Study name	Group	Respiratory diseases	Renal diseases	Cardiovascular diseases	Hypertension	Diabetes	Immunosuppressed
Entrenas Castillo et al. (2020) [17]	COVID-19 “D” (N = 50)	4 (8%)	0	2 (4%)	11 (24.19%)	3 (6%)	6 (12%)
Entrenas Castillo et al. (2020) [17]	COVID-19 (N = 26)	2 (7.69%)	0	1 (3.85%)	15 (57.69%)	5 (19.23%)	1 (3.85%)
Hernández et al. (2020) [19]	COVID-19 “D” (N = 19)	2 (10.5%) ∞	NM	3 (15.8%)	12 (63.2%)	0	6 (31.6%)
Hernández et al. (2020) [19]	COVID-19 (N = 197)	15 (7.6%) ∞	NM	21 (10.7%)	76 (38.6%)	34 (17.3%)	16 (8.1%)
Murai et al. (2020) [18]	COVID-19 “D” (N = 120)	7 (5.8%) ∞ 7 (5.8%) α	2 (1.6%)	16 (13.3%)	67 (55.8%)	49 (40.8%)	NM
Murai et al. (2020) [18]	COVID-19 (N = 120)	5 (4.1%) ∞ 7 (5.8%) α	0	16 (13.3%)	58 (48.3%)	35 (29.1%)	NM
Ye et al. (2020) [14]	COVID-19 “P” (N = 62)	1 (1.6%) ∞ 0 α	16 (25.8%)	NM	6 (9.6%)	5 (8.06%)	NM
Ye et al. (2020) [14]	COVID-19 “N” (N = 80)	NM	NM	NM	NM	NM	NM
Abdollahi et al. (2020) [15]	COVID-19 “P” (N = 201)	14 (6.96%)	NM	20 (9.95%) [cardiovascular + hypertension]		42 (20.89%)	4 (1.99%)
Abdollahi et al. (2020) [15]	COVID-19 “N” (N = 201)	8 (39.80%)	NM	15 (7.46%) [cardiovascular + hypertension]		19 (9.45%)	1 (0.49%)